Skip to main content

Personalisation of tREatment In Cardiovascular disease through next generation sequencing in Adverse Drug Reactions

Objective

Prediction-ADR aims to discover the genetic factors predisposing patients to adverse drug reactions (ADRs) from cardiovascular disease (CVD) drugs. This will be achieved by assembling a consented blood bank and DNA for a population of ~500 cases of ACEi induced angioedema and statin induced myopathy defined using a standardised phenotypic criteria. An innovative next generation sequencing strategy will be used to find predisposing genetic changes to myopathy and angioedema. Our SME partner will use proprietary software to build a highly predictive genetic algorithm for subsequent performance evaluation in real world clinical datasets involving >50,000 patients. This will deliver a novel set of genomic biomarkers to improve effective prevention or treatment of CVD providing the EU SME competitive advantage in the emerging personalised medicine market. The number of CVD drug prescriptions globally means that the absolute number of adverse drug reactions (ADRs) is substantial resulting in harm to the patients and leading to discontinuation and increased risk of CVD progression. Genome wide association studies (GWAS) has recently accelerated the progress in determining genetic biomarkers for adverse responses to drugs and with the advent of affordable whole genome sequencing, genetic research is now positioned to accelerating it even further. This provides a new opportunity to discover improved genomic biomarkers for extreme phenotypes of severe ADRs. The ultimate goal is to have these markers accepted by EMA and FDA and to disseminate these findings not only to the scientific community but also to lay people and patient organisations. This genetic algorithm will be developed into a commercially available clinical test by Asper Biotech. As 7 Million individuals were treated with statins in the UK alone during 2012, the size of the potential market for this test is immense.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /natural sciences/computer and information sciences/software
  • /natural sciences/biological sciences/genetics and heredity/genome
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/adverse drug reactions

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

UNIVERSITY OF DUNDEE
Address
Nethergate
DD1 4HN Dundee
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 762 664
Administrative Contact
Vicki Gilbert (Mrs.)

Participants (6)

UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 507 838
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
Administrative Contact
R. De Kok-Baan (Mrs.)
THE UNIVERSITY OF LIVERPOOL
United Kingdom
EU contribution
€ 640 801
Address
Brownlow Hill 765 Foundation Building
L69 7ZX Liverpool
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jenny Lawson (Ms.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 632 604
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mikael Widell (Mr.)
PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED

Participation ended

United Kingdom
EU contribution
€ 22 645,39
Address
Aston Court Kingsmead Business Park
HP11 1LA High Wycombe Bucks
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alun Mccarthy (Dr.)
ASPER BIOTECH AS
Estonia
EU contribution
€ 158 382
Address
Vaksali 17A
50410 Tartu
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anu Aaspõllu (Dr.)
ADORIAL TECHNOLOGIES LTD
United Kingdom
EU contribution
€ 275 017,61
Address
Aston Court Kingsmead Business Park
HP11 1LA High Wycombe
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alun Mccarthy (Dr.)